Molecular analysis of CDKN2 (p16) in gliomas associated with clinical data.
We analyzed alterations in CDKN2 in gliomas from an ethically mixed population and correlated the results with patients clinical data. We screened for methylation at CDKN2 and for microsatellite instability (MSI) and loss of heterozygosity (LOH) in the region 9p21-22 using 4 markers. We found: 3/30 (10%) cases with CDKN2-methylated gliomas; an average of 4% of MSI; and 24.5% of LOH in the region 9p21-22. Methylation of CDKN2 was only detected in patients showing high-grade gliomas with short survival. MSI and LOH in the region 9p21-22 were detected in patients showing high-grade gliomas with short survival and in one patient with a recurrent low-grade astrocytoma grade II who died from the disease after 3 years, indicating that such alterations represent poor prognosis.